BRRGF (Oncoinvent ASA) Other Stockholders Equity: $1.33 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRRGF Oncoinvent ASA BRRGF
36 GF Score
Price $97.09
GF Value $1,271.07
! 5 Warning Signs
View Full Analysis

What is Oncoinvent ASA Other Stockholders Equity?

Oncoinvent ASA BRRGF 36 Other Stockholders Equity is $1.33 Mil as of Dec. 2025. GuruFocus rates BRRGF with a GF Score™ of 36/100 and a GF Value™ of $1,271.07. The stock has 5 warning signs investors should review.

Oncoinvent ASA's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $1.33 Mil.

Oncoinvent ASA's quarterly Other Stockholders Equity declined from Dec. 2024 ($0.86 Mil) to Jun. 2025 ($0.00 Mil) but then increased from Jun. 2025 ($0.00 Mil) to Dec. 2025 ($1.33 Mil).

Oncoinvent ASA's annual Other Stockholders Equity increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.86 Mil) and increased from Dec. 2024 ($0.86 Mil) to Dec. 2025 ($1.33 Mil).

Oncoinvent ASA Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Other Stockholders Equity Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.86 1.33

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.86 0.00 1.33
BRRGF
36GF Score
Oncoinvent ASA BRRGF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $1.33 Mil mean?
Oncoinvent ASA (BRRGF) has a Other Stockholders Equity of $1.33 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Other Stockholders Equity too high?
Oncoinvent ASA's current Other Stockholders Equity is $1.33 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Other Stockholders Equity compare to VRTX and REGN?
Oncoinvent ASA's Other Stockholders Equity of $1.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Other Stockholders Equity is $1.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (BRRGF) has a current Other Stockholders Equity of $1.33 Mil. The stock's GF Value™ is $1,271.07, compared to a current price of $97.09 — trading 92.4% below its estimated fair value. The current Other Stockholders Equity is $1.33 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Oncoinvent ASA (BRRGF), the current Other Stockholders Equity is $1.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (BRRGF) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of $97.09 is trading 92.4% below its estimated GF Value™ of $1,271.07.

Key valuation signals for BRRGF:

  • Other Stockholders Equity: $1.33 Mil
  • GF Value™: $1,271.07 vs. price of $97.09 (92.4% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the BRRGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for BRRGF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$97.09
Price
$1,271.07
GF Value